Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.09.1451 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.09.1451 33002616!7521368!33002616     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2020 ; 101 (ä): 191-193 Nephropedia Template TP {{tp|p=33002616|t=2020. Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia |pdf=|usr=}}{{33002616}} gab.com Text Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33002616 #FOAvip OBJECTIVES: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. METHODS: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. RESULTS: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. CONCLUSIONS: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus. Twit Text FOAVip Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33002616 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33002616 #FOAvip English Wikipedia <ref>{{Cite pmid|33002616}}</ref> Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia #MMPMID33002616 Faccini-Martinez AA; Rivero R; Garay E; Garcia A; Mattar S; Botero Y; Galeano K; Miranda J; Martinez C; Guzman C; Arrieta G; Contreras H; Kerguelen H; Moscote M; Brango E; Contreras V Int J Infect Dis 2020[Dec]; 101 (ä): 191-193 PMID33002616show ga OBJECTIVES: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. METHODS: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. RESULTS: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. CONCLUSIONS: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus. |*Cross Reactions[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Antibodies, Viral/blood/*immunology[MESH] |COVID-19/blood/epidemiology/*immunology/virology[MESH] |Child[MESH] |Child, Preschool[MESH] |Colombia/epidemiology[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |SARS-CoV-2/*immunology[MESH] |Young Adult[MESH] |Zika Virus Infection/blood/epidemiology/*immunology/virology[MESH]Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zi(epmc).pdf DeepDyve Pubget Overpricing